Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

Slides:



Advertisements
Similar presentations
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Advertisements

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Value in Health Regional Issues
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting  Adnan Said, John Williams, Jeremy Holden,
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
The Aging Liver in the Aging HIV and HCV Patients
Volume 42, Issue 6, Pages (June 2005)
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Hepatitis C in the rituximab era
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Bleeding in carriers of hemophilia
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,
Nonmyeloablative conditioning for relapsed follicular lymphoma
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Genetic sequence analysis of inherited bleeding diseases
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.
Hepatitis C in the HIV-infected patient
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
How we choose factor VIII to treat hemophilia
The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting  Adnan Said, John Williams, Jeremy Holden,
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert
Value in Health Regional Issues
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.
Stage C or not stage C…? by Claire Dearden Blood
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.
Sabina Kersting, Leo F. Verdonck 
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Hashem B. El-Serag, Thomas P
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A
a) Mortality per time point (p<0
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection  Yi–Cheng Chen, I.–Shyan Sheen,
Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.
A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan  Yi-Chun.
Rituximab immunotherapy: it’s getting personal
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.
Balancing bleeding in brain metastases
Cold agglutinin disease
New concepts for anticoagulant therapy in persons with hemophilia
Presentation transcript:

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk Posthouwer, Michael Makris, Thynn T. Yee, Kathelijn Fischer, Joost J. van Veen, Anja Griffioen, Karel J. van Erpecum, and Eveline P. Mauser-Bunschoten Blood Volume 109(9):3667-3671 May 1, 2007 ©2007 by American Society of Hematology

Cumulative incidences of ESLD in 687 patients with chronic hepatitis C and in 160 patients who spontaneously cleared HCV. Cumulative incidences of ESLD in 687 patients with chronic hepatitis C and in 160 patients who spontaneously cleared HCV. Dirk Posthouwer et al. Blood 2007;109:3667-3671 ©2007 by American Society of Hematology

Cumulative incidences of ESLD in patients with chronic hepatitis C according to their HIV status. Cumulative incidences of ESLD in patients with chronic hepatitis C according to their HIV status. A total of 190 patients were HIV+ and 497 HIV−. Dirk Posthouwer et al. Blood 2007;109:3667-3671 ©2007 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.